Transitioning From S1P Receptor Modulators to B Cell-Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data.

William M RowlesWan-Yu HsuKira McPolinAlyssa LiSteven MerrillChu-Yueh GuoAri J GreenJeffrey Marc Gelfand Riley M Bove

Published in: Neurology(R) neuroimmunology & neuroinflammation (2022)

Delaying anti-CD20 start to monitor ALC after S1P modulator discontinuation may not be necessary and could increase rebound risk. ALC monitoring could instead occur after a rapid switch to anti-CD20 treatment.

Keyphrases

multiple sclerosis
small molecule
electronic health record
big data
machine learning
artificial intelligence
loop mediated isothermal amplification